Previous close | 1.6600 |
Open | 1.6700 |
Bid | 1.4800 x 100 |
Ask | 1.6000 x 100 |
Day's range | 1.5020 - 1.6700 |
52-week range | 1.4000 - 18.0000 |
Volume | |
Avg. volume | 1,645,261 |
Market cap | 4.455M |
Beta (5Y monthly) | 0.52 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.4800 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 80.00 |
NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more patients due to an increase in distribution of 5-FU to cancer cells Phase 1b study final results to be released upon database lock HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focus
Insiders who bought US$210.6k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference. David Young, Processa’s President of Research & Developm